Therapy for Parkinson's disease: what is in the pipeline? (Q26991826)

Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Animal models of Parkinson's disease: a gateway to therapeutics?

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Gene-based therapies in Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Emerging therapies for Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Therapies in Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

IPX066: a novel carbidopa-levodopa extended-release formulation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Future treatments for Parkinson's disease: surfing the PD pipeline

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

The Parkinson Progression Marker Initiative (PPMI).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Milestones in PD genetics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Preclinical biomarkers of Parkinson disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Genetic animal models of Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Targeting adenosine A2A receptors in Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

ACP-103, a 5-HT2A receptor inverse agonist

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Levodopa-induced dyskinesia in Parkinson's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Levodopa and the progression of Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Zonisamide has beneficial effects on Parkinson's disease patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Slowing the progression of Alzheimer disease: methodologic issues

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Improvement of motor function in early Parkinson disease by safinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0242-1

Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899489

Modeling Parkinson's disease

28 November 2018

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

1 reference

12 December 2020

The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations

1 reference

12 December 2020

Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations

1 reference

12 December 2020

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

1 reference

12 December 2020

Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion

1 reference

12 December 2020

Pathogenesis of Parkinson's disease

1 reference

12 December 2020

A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease

1 reference

12 December 2020

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

12 December 2020

Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial

1 reference

12 December 2020

10.1007/S13311-013-0242-1

Identifiers

DOI

1 reference

Dimensions Publication ID

1035359392

0 references

1 reference

1 reference

PubMed publication ID

24343458

1 reference